Hematopoiesis News 9.40 October 9, 2018 | |
| |
TOP STORYLate-Stage Tumors Induce Anemia and Immunosuppressive Extramedullary Erythroid Progenitor Cells Researchers identified CD45+ erythroid progenitor cells (EPCs) as robust immunosuppressors. CD45CD45+ EPCs, induced by tumor growth-associated extramedullary hematopoiesis, accumulated in the spleen to become a major population, outnumbering regulatory T cells and myeloid-derived suppressor cells. [Nat Med] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists identified cyclin D2 (CCND2) as a crucial transmitter of RUNX1/ETO-driven leukemic propagation. Knockdown or pharmacological inhibition of CCND2 by an approved drug significantly impaired leukemic expansion of patient-derived acute myeloid leukemia cells and engraftment in immunodeficient murine hosts. [Cancer Cell] Full Article | Press Release | Graphical Abstract Researchers found two daily peaks of bone marrow hematopoietic stem and progenitor cell (HSPC) activity that were initiated by the onset of light and darkness. Light-induced norepinephrine and TNF secretion augmented HSPC differentiation and increased vascular permeability to replenish the blood. [Cell Stem Cell] Abstract | Full Article | Graphical Abstract Investigators showed that, in human, the first lineage restriction events occurred within the CD19−CD34+CD38−CD45RA−CD49f+CD90+ HSC compartment to generate myelo-lymphoid committed cells with no erythroid differentiation capacity. [Nat Commun] Full Article | Press Release Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Patients Researchers reported bone marrow (BM) hematopoietic dysfunction in early and late stage untreated B-chronic lymphocytic leukemia patients. Numbers of CD34+ BM hematopoietic progenitors responsive in standard colony-forming unit assays were significantly reduced. [Leukemia] Abstract Kinetics of Adult Hematopoietic Stem Cell Differentiation In Vivo Scientists combined inducible lineage tracing of endogenous adult HSCs with flow cytometry and single-cell RNA sequencing to characterize early steps of hematopoietic differentiation in the steady-state. [J Exp Med] Abstract | Graphical Abstract Histone Methylation Regulator PTIP Is Required to Maintain Normal and Leukemic Bone Marrow Niches Scientists found that the histone methylation regulator Pax interaction with transcription-activation domain protein-1 (PTIP) was required to maintain the integrity of the bone marrow (BM) niche by promoting osteoclast differentiation. PTIP deletion led to a drastic reduction of HSCs in the BM and induced extramedullary hematopoiesis. [Proc Natl Acad Sci USA] Abstract Generation of Clinical-Grade Red Blood Cells from Human Umbilical Cord Blood Mononuclear Cells A xeno-free method for ex vivo generation of red blood cells (RBCs) was attempted in order to replicate for large-scale production and clinical applications. The strategy adopted included a combination of erythropoietin and other injectable drugs under low oxygen levels, which resulted in an increase in the number of mature RBCs produced in vitro. [Cell Tissue Res] Abstract CLINICAL RESEARCHThe Phase III DUO Trial: Duvelisib versus Ofatumumab in Relapsed and Refractory CLL/SLL Scientists report the results of DUO™, a global Phase III randomized study of duvelisib versus ofatumumab monotherapy for patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. [Blood] Abstract | Full Article | Press Release | Editorial In this trial, hematopoietic cell transplantation-comorbidity index at the time of HSC transplantation (HSCT) and response to azacitidine were independent predictors of overall survival, underlining the importance of disease-debulking before HSCT. [Leukemia] Abstract Ropeginterferon Alpha-2b Targets JAK2V617F-Positive Polycythemia Vera Cells In Vitro and In Vivo Ropeginterferon was able to inhibit the proliferation of HEL, UKE-1, and UT-7 JAK2-mutant cell lines while sparing JAK2-wild-type UT-7 and normal CD34+ cells growth. In vitro treatment of erythroid progenitors derived from polycythemia vera patients showed that ropeginterferon could considerably inhibit the growth of endogenous erythroid colonies, a hallmark of polycythemia vera. [Blood Cancer J] Full Article Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSHematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy The recent results of CAR-T cell therapy raise the question of how best to integrate CAR-T cell therapy and allogeneic hematopoietic cell transplantation in the care of patients with CD19+ B cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia. [Curr Hematol Malig Rep] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSCyclacel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome and other advanced leukemias. [Cyclacel Pharmaceuticals, Inc.] Press Release Blood Researcher Receives NIH New Innovator Award The National Institutes of Health (NIH) announced that stem cell biologist Sergei Doulatov, assistant professor of medicine, Division of Hematology, at the University of Washington School of Medicine will receive an NIH Director’s New Innovator Award. [University of Washington] Press Release FDA Approves Roche’s Hemlibra for Hemophilia A without Factor VIII Inhibitors Roche announced that the FDA has approved Hemlibra® for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors. [F. Hoffmann-La Roche Ltd] Press Release Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase I Program on Clinical Hold Affimed N.V. announced that it has placed AFM11 on clinical hold, and has notified the global health authorities of its decision. The clinical hold was initiated after the occurrence of serious adverse events in three patients, which included a death in the acute lymphoblastic leukemia study and two life-threatening events in the non-Hodgkin lymphoma study. [Affimed N.V.] Press Release | |
| |
POLICY NEWSWas Cancer Scientist Fired for Challenging Lab Chief over Authorship? Rutgers University last month terminated a veteran cancer scientist in retaliation, the researcher says, for challenging a powerful principal investigator on the authorship of a paper apparently accepted for publication in Nature. The researcher is now deciding whether to appeal her dismissal in arbitration through her union or to sue Rutgers. [ScienceInsider] Editorial Industry Partners Extensively Involved in Trials They Fund Industry funders are usually involved in every stage of the clinical trials they support, and may try to downplay their involvement when trial results are reported, according to a study led by researchers in Denmark published in BMJ. The findings suggest that industry funders may be wielding greater influence over how trials are conducted and how results are published than currently realized. [The Scientist] Editorial Columbia University Postdocs Vote to Unionize Postdocs at Columbia University voted to unionize, with representation from the United Auto Workers, according to The Associated Press. The organization represents the first postdoc union at a private university in the United States. [The Scientist] Editorial Questions about Funding and Purpose Loom over a Foundation Congress Created to Help the FDA The Reagan-Udall Foundation for the FDA is supposed to act as a liaison between the FDA itself and drug companies, researchers, nonprofits, or other businesses with regulated products who might want to support a project to make the agency’s job easier. It has raised just under $15 million during its first decade, according to the foundation. [STAT News] Editorial
| |
EVENTSNEW Keystone Symposia: Cellular Plasticity: Reprogramming, Regeneration and Metaplasia Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position or PhD Student – Bioinformatics in Leukemia (RWTH Aachen Medical School) NEW Postdoctoral Fellowship – Translational Leukemia Research (Lund University) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Postdoctoral Fellow – Myelodysplasia and Acute Myeloid Leukemia (University of New South Wales) Postdoctoral Fellow – Immunology/Hematopoiesis (Lund University) Postdoctoral Position – Stem Cells, Development and Cancer (Albert Einstein College of Medicine) Postdoctoral Fellow – Leukemic Stem Cell Biology (McGill University) Senior Scientist – CAR T-Cell Research (CELLECTIS Inc.) Faculty Position – Hematopathologist (St. Jude Children’s Research Hospital) Postdoctoral Fellow – Aging of Hematopoietic Stem Cells (City of Hope) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|